These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 20973982

  • 41. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A.
    Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
    [Abstract] [Full Text] [Related]

  • 42. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW, Chang CH.
    Perit Dial Int; 2009; 29(2):199-203. PubMed ID: 19293358
    [Abstract] [Full Text] [Related]

  • 43. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia.
    Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson DM, Mattar BI, Moore DF, Nikcevich D, Loprinzi CL.
    Am J Hematol; 2015 Oct; 90(10):877-81. PubMed ID: 26149465
    [Abstract] [Full Text] [Related]

  • 48. The MAINTAIN study--managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin.
    Watschinger B, Salmhofer H, Horn S, Neyer U, Wiesinger T, Wiesholzer M, Erb H, Jaeger C, Hemetsberger M, Rosenkranz AR.
    Wien Klin Wochenschr; 2013 Feb; 125(3-4):71-82. PubMed ID: 23299452
    [Abstract] [Full Text] [Related]

  • 49. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD, Kolmakova E, Fung M, Malecki R, Vinhas J, Dellanna F, Thomas M, Manamley N, Ferenczi S.
    Nephrology (Carlton); 2014 May; 19(5):266-74. PubMed ID: 24506498
    [Abstract] [Full Text] [Related]

  • 50. [Cost-effectiveness of darbepoetin alpha in an every-3-weeks schedule].
    Borget I, Chouaid C, Demarteau N, Annemans L, Pujol JL.
    Bull Cancer; 2008 Apr; 95(4):465-73. PubMed ID: 18495577
    [Abstract] [Full Text] [Related]

  • 51. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents.
    Silver MR, Geronemus R, Krause M, Chen CY, Kewalramani R, Stehman-Breen C.
    Curr Med Res Opin; 2009 Jan; 25(1):123-31. PubMed ID: 19210145
    [Abstract] [Full Text] [Related]

  • 52. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
    Glaspy J.
    Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):29-32. PubMed ID: 16925109
    [Abstract] [Full Text] [Related]

  • 53. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
    Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J, Aranesp 980297 Study Group.
    J Natl Cancer Inst; 2002 Aug 21; 94(16):1211-20. PubMed ID: 12189224
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease.
    Provenzano R, Singh AK.
    Endocr Pract; 2007 Aug 21; 13(3):251-9. PubMed ID: 17599856
    [Abstract] [Full Text] [Related]

  • 56. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF.
    Cancer Treat Rev; 2006 Aug 21; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [Abstract] [Full Text] [Related]

  • 57. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY, Chu TS, Huang JW, Wu MS, Wu KD.
    J Formos Med Assoc; 2008 Nov 21; 107(11):843-50. PubMed ID: 18971153
    [Abstract] [Full Text] [Related]

  • 58. A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Mel JR, Salar A, Rodríguez CA, Alegre A, González A, Cassinello J, Montesinos J, Gasquet JA, Sánchez J, Saigí E, AMG-DAR-2002-01 Study Group.
    Curr Med Res Opin; 2008 Oct 21; 24(10):2931-42. PubMed ID: 18775103
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ, Glaspy JA, Adams JL, Mafilios MS, Wang SM, Viswanathan HN, Kallich JD.
    J Med Econ; 2008 Oct 21; 11(2):199-213. PubMed ID: 19450080
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.